|
|
Upfront Briefing
Samsung Biologics just wrote the biggest cheque in Korean biopharma history — CHF 1.46B for Swiss peptide CDMO PolyPeptide, with the board and a 55.65% holder already on side. The strategic tell is obvious: everyone needs GLP-1 peptide capacity, nobody can build it fast enough, so you buy it. Elsewhere the weekend belonged to durability data, with Insmed and 4DMT both extending follow-up on assets the Street has been underwriting on shorter curves.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,457.7 |
(1.0%) |
+8.7% |
| Nasdaq 100 |
28,592.7 |
(1.5%) |
+13.4% |
| Russell 2000 |
2,962.2 |
(0.4%) |
+18.1% |
| Healthcare (XLV) |
161.1 |
(0.4%) |
+3.6% |
| Biotech (XBI) |
154.3 |
+1.5% |
+26.9% |
| Nasdaq Biotech (NBI) |
6,564.4 |
+0.3% |
+15.0% |
| Clinical Trials (BBC) |
51.0 |
+2.1% |
+35.5% |
|
- Biotech decoupled from the selloff, with XBI up 1.5% and BBC up 2.1% against a falling tape, as Lilly's $2.8B AtaiBeckley acquisition and Novartis's Fabhalta conversion to full approval kept M&A and regulatory momentum intact; GSK's camlipixant discontinuation stayed contained to GSK rather than bleeding into sector beta.
- The broad tape broke on semiconductors: Chinese startup Moonshot AI released a frontier open model that revived doubts over hyperscaler AI capex, pushing the PHLX Semiconductor Index into a bear market and dragging the Nasdaq Composite down 1.4%, while renewed U.S.–Iran escalation lifted crude and left energy as the only S&P sector in the green.
- Market data: U.S. cash close Friday, 17 July 2026.
The Big 3
|
1
|
Samsung Biologics bids CHF 1.46B for PolyPeptide
|
- Samsung Biologics pre-announced an all-cash tender for 100% of Swiss peptide CDMO PolyPeptide at CHF 44.31 per share, an implied equity value of about CHF 1.46B ($1.8B) and a 40% premium to the undisturbed 10 April close of CHF 31.65.
- Why it matters: Samsung is paying roughly 3.3x annualised H1 revenue — PolyPeptide turned over $271M in the half, up 41.6% — for the one input it cannot build on its own timeline. Peptide API capacity is the bottleneck in GLP-1 supply and greenfield is a multi-year project. The arb is tight rather than free: Draupnir's 55.65% is irrevocably committed against a 66⅔% minimum, so roughly 11 points of float decide it, and the tender doesn't open until end-August against a year-end close. Bachem is the read-across on any re-rate of listed peptide capacity. Samsung has said it will part-fund with borrowings without disclosing the split.
-
Source:
CNBC
-
More:
Korea Herald;
Reuters;
PR
|
|
2
|
Insmed's 12-month PAH data firms up a $6B sell-side case
|
- Insmed reported 12-month open-label extension data for TPIP in pulmonary arterial hypertension, with gains sustained across six-minute walk distance, NT-proBNP and WHO functional class.
- Why it matters: The number that matters is the crossover arm. Patients switched off placebo gained 54.1m on six-minute walk distance against 55.7m for those on TPIP throughout, with NT-proBNP down about 60% in both and roughly 80% reaching WHO Functional Class I or II. Late starters catching up is the cleanest read-through to PALM-PAH, since it suggests the effect doesn't hinge on early initiation. The caveats are real: n=60 and n=31 respectively, and Truist has flagged an efficacy ceiling. The $6B is Guggenheim's peak-sales estimate across multiple indications, not company guidance, and it assumes TPIP takes share from Liquidia's Yutrepia and United Therapeutics' Tyvaso DPI on convenience.
-
Source:
BioSpace
|
| 3 | 4DMT posts two-year PRISM data in wet AMD |
-
4DMT reported positive two-year Phase 2b PRISM results for 4D-150 in a broad wet AMD population.
-
Why it matters:
Two years out, the 45-patient cohort needed 2.7 supplemental injections against 12.0 projected on aflibercept Q8W — a 78% cut, rising to 87% in recently diagnosed patients. Vision was maintained rather than improved, and that's the tension worth sitting with: 4FRONT is designed as a BCVA non-inferiority study against aflibercept Q8W, so the pivotal reads out on the endpoint where 4D-150 only has to match, while the entire commercial case rests on burden. Safety holds at the Phase 3 dose (n=71, 2.8% mild transient inflammation). Financing risk has largely closed out — 4FRONT-2 finished enrolling in late June alongside a $200M Hercules facility — leaving execution and durability.
-
Source:
PR
-
More:
REGENXBIO / ASRS
|
Everything Else that broke
- GSK confirmed it has ended camlipixant development after mixed CALM-1 and CALM-2 Phase 3 results in refractory chronic cough. — Fierce Biotech
- Mission Therapeutics handed acute kidney injury asset MTX652 to Dimerix for $5M upfront plus up to $287M in milestones. — Fierce Biotech
- REGENXBIO showed surabgene lomparvovec vision durability through 5 years in wet AMD at ASRS. — PR
- Lundbeck closed randomization in DEEp OCEAN, a 340-patient Phase III of bexicaserin across DEE subtypes, with headline results guided to end-Q4 2026 or Q1 2027. — PR
- FDA said Makary and Prasad journal papers do not represent agency policy. — BioSpace
- The EU approved JASCAYD for IPF and PPF. — PR
- FDA scrutiny persists at Novo and Alvotech plants tied to recent rejections. — Fierce Pharma
- Abbott beat Q2 expectations and raised its 2026 profit forecast. — Fierce Biotech
- Kyverna moved toward what could be the first autoimmune cell therapy filing. — BioSpace
- Peptides and RP1 advisory panels are shaping up as an FDA credibility test. — BioCentury
- CRISPR co-inventor Jennifer Doudna is moving into AI-driven protein design. — Fierce Biotech
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Samsung Biologics pre-announced an all-cash tender for PolyPeptide at CHF 44.31 per share, implying CHF 1.46B ($1.8B) of equity value; tender opens end-August, targeted close year-end. — CNBC
- Dimerix licensed Mission Therapeutics' Phase 2-ready acute kidney injury asset MTX652 for $5M upfront plus up to $287M in milestones. — Fierce Biotech
- Jasper completed its all-stock acquisition of Kira and offloaded its Tavneos rival to Mirador under a parallel licensing agreement. — Fierce Biotech
- Biotronik Neuro bought Soin Neuroscience's spinal cord stimulation patent portfolio. — Fierce Biotech
VC / Private Financings
- RapidPulse closed an oversubscribed $48M Series B co-led by Medtronic, TechWald Next and S3 Ventures, with SBI Investment, Florida Opportunity Fund, Santé Ventures, Syntheon, Hatteras Venture Partners and Epidarex Capital also participating. — PR
- Trellis Bioscience closed a $9M Series C to advance calpurbatug (TRL1068) in infectious disease. — PR
IPOs / Follow-Ons
- Latigo Biotherapeutics filed to go public, funding a non-opioid pain pipeline positioned against Vertex's Journax. — Fierce Biotech
- BlossomHill Therapeutics filed its S-1, taking a small-molecule oncology pipeline into a crowded IPO queue. — Endpoints
- DBV filed an ATM prospectus for up to $150M of share sales. — PR
|
Samsung just paid $1.8B to skip the queue for peptide capacity. Somewhere, a capex committee is having a long Monday.
— BioBucks Team
|
|
|
